Agentix Corp. has shifted from composite products manufacturing to clinical-stage biopharmaceutical development, focusing on peripherally-restricted CB1 receptor antagonists for conditions such as Type 2 diabetes and obesity. Despite exclusive worldwide licenses for promising compounds AGTX-2004 and AGTX-2003, the company remains pre-revenue, operating at net losses with fragile liquidity. Progress includes IND clearance and upcoming Phase 1 trials, yet ongoing cash flow deficits and high debt levels raise substantial doubt about its going concern status. Future growth hinges on successful clinical milestones and capital raises amid stiff competition and regulatory complexities in the biopharma space.